Ron Martell
Known title: President, CEO and DirectorCIK: 0001177079
Ron Martell's purchase track record
Ron Martell has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/22/2025 | JSPR | $100K | -24.8% | -53.1% | -1.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| JSPR | ▲ Buy | Open Market | 41,000 | $100K | 9/22/2025 | View on chart |
| JSPR | ▼ Sell | Tax Withholding | 87,531 | $74K | 10/12/2023 | View on chart |
| JSPR | ▼ Sell | Tax Withholding | 87,531 | $128K | 4/12/2023 | View on chart |
| JSPR | ▲ Buy | Grant | 506,250 | $0 | 10/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO
Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.